Overall survival and event-free survival of AML-MK at 3 years after diagnosis and after allogeneic stem cell transplantation in AML-MK in relation to the specific cytogenetic abnormalities abn(17p) or −5/del(5q)
| Chromosomal abnormality . | After diagnosis . | After allogeneic stem cell transplantation . | ||||
|---|---|---|---|---|---|---|
| No. . | OS (SE) at 3 y . | EFS (SE) at 3 y . | No. . | OS (SE) at 3 y . | EFS (SE) at 3 y . | |
| MK total | 305 | 7 (1) | 5 (1) | 49 | 28 (6) | 26 (6) |
| With abn(17p) | 38 | 5 (4) | 5 (4) | 7 | 29 (17) | 29 (17) |
| Without abn(17p) | 267 | 7 (2) P = .90 | 6 (1) P = .79 | 42 | 28 (7) P = .93 | 25 (7) P = .81 |
| With −5/del(5q) | 172 | 2 (1) | 2 (1) | 25 | 16 (7) | 11 (7) |
| Without −5/del(5q) | 133 | 12 (2) P < .01 | 10 (3) P = .02 | 24 | 41 (10) P = .06 | 41 (10) P = .03 |
| Non-MK abnormalities | 804 | 35 (2) | 25 (2) | 223 | 54 (3) | 51 (3) |
| Chromosomal abnormality . | After diagnosis . | After allogeneic stem cell transplantation . | ||||
|---|---|---|---|---|---|---|
| No. . | OS (SE) at 3 y . | EFS (SE) at 3 y . | No. . | OS (SE) at 3 y . | EFS (SE) at 3 y . | |
| MK total | 305 | 7 (1) | 5 (1) | 49 | 28 (6) | 26 (6) |
| With abn(17p) | 38 | 5 (4) | 5 (4) | 7 | 29 (17) | 29 (17) |
| Without abn(17p) | 267 | 7 (2) P = .90 | 6 (1) P = .79 | 42 | 28 (7) P = .93 | 25 (7) P = .81 |
| With −5/del(5q) | 172 | 2 (1) | 2 (1) | 25 | 16 (7) | 11 (7) |
| Without −5/del(5q) | 133 | 12 (2) P < .01 | 10 (3) P = .02 | 24 | 41 (10) P = .06 | 41 (10) P = .03 |
| Non-MK abnormalities | 804 | 35 (2) | 25 (2) | 223 | 54 (3) | 51 (3) |
AML patients with normal karyotypes, core binding factor abnormalities, or sole –X of –Y were excluded. Non-MK abnormalities refers to AML not meeting the definition MK but with other non–core binding factor cytogenetic abnormalities as previously described.1
SE, standard error.